logo.jpg
Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
September 20, 2021 17:00 ET | Genmab A/S
TIVDAK is a First-in-Class Antibody-Drug Conjugate Directed to Tissue Factor, a Protein Expressed on Cervical Cancer CellsNew Monotherapy Approved for Use in a Cancer with Limited Treatment Options ...
researchdrivelogo.jpg
Global Human Papillomavirus Vaccine Market Estimated to Generate a Revenue of $9,283.6 Million By 2027, Growing at a CAGR of 12.0% from 2020-2027 – Informative Report [238 Pages] by Research Dive
August 03, 2021 09:27 ET | Research Dive
New York, USA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- According to a report published by Research Dive, the global human papillomavirus vaccine market is expected to generate a revenue of $9,283.6...
FBI LOGO TM.png
Report 2021, Cervical Cancer Screening Market | Global Size, Share, Growth, Trends, Revenue Analysis, Competitive Landscape, Forecast 2028
July 22, 2021 02:58 ET | Fortune Business Insights
Pune, India, July 22, 2021 (GLOBE NEWSWIRE) -- The global cervical cancer screening market size is expected to gain momentum owing to the increasing prevalence of cancer during the forecast period....
logo.jpg
Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
April 09, 2021 16:00 ET | Genmab A/S
Company Announcement FDA action date is Oct 10, 2021BLA submission supported by positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress...
logo.jpg
Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
February 10, 2021 16:05 ET | Genmab A/S
Company Announcement Submission based on positive pivotal innovaTV 204 trial results presented at the European Society of Medical Oncology Virtual Congress 2020 COPENHAGEN, Denmark and BOTHELL,...
ResearchDriveLogo.jpg
Global Human Papillomavirus Vaccine Market Projected to Reach up to $9,283.6 Million and Rise at a CAGR of 12.0% from 2020 to 2027 – Exclusive Report [238 Pages] by Research Dive
February 10, 2021 09:15 ET | Research Dive
New York, USA, Feb. 10, 2021 (GLOBE NEWSWIRE) -- According to a newly published report by Research Dive, the global human papillomavirus vaccine market is estimated to generate $9,283.6 million by...
logo.jpg
Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
January 04, 2021 14:00 ET | Genmab A/S
Media Release COPENHAGEN, Denmark, Jan. 04, 2021 Initiation of a global phase 3 trial for tisotumab vedotin versus investigator’s choice chemotherapy in recurrent or metastatic cervical cancer ...
Reports and Data.jpeg-01
Oncology Molecular Diagnostics Market to Reach USD 3,568.1 Million By 2027 | Reports and Data
December 15, 2020 09:17 ET | Reports and Data
New York, Dec. 15, 2020 (GLOBE NEWSWIRE) -- The global oncology molecular diagnostics market size is forecast to reach USD 3,568.1 Million by 2027, according to a new report by Reports and Data. The...
logo.jpg
Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
September 21, 2020 10:20 ET | Genmab A/S
Media Release COPENHAGEN, Denmark and BOTHELL, Wash., 21 September 2020 Data featured in late-breaking proffered paper oral presentation  Biologics license application submission planned to support...
logo.jpg
Genmab Announces Late-Breaking Oral Presentation of Phase 2 innovaTV 204 Study at the ESMO Virtual Congress 2020
August 26, 2020 18:05 ET | Genmab A/S
Media Release Copenhagen, Denmark, Aug 27, 2020 InnovaTV 204 study evaluated tisotumab vedotin in recurrent or metastatic cervical cancer Data from the study selected as a late-breaking abstract at...